Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Liao, Haihui ^a   Irvine, Alan D ^b,c   MacEwen, Caroline J ^d   Weed, Kathryn H ^d   Porter, Louise ^a   Corden, Laura D ^a   Gibson, A Bethany ^a   Moore, Jonathan E ^e   Smith, Frances J D ^a   McLean, W H Irwin ^a   Moore, C B Tara ^a,e  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ARGININE; CYTOSINE; GUANOSINE; KERATIN; LEUCINE; PROLINE; SMALL INTERFERING RNA; THREONINE; THYMINE; MUTANT PROTEIN;

ALLELE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEESMANN CORNEAL DYSTROPHY; MISSENSE MUTATION; PHENOTYPE; PROTEIN EXPRESSION; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLIT LAMP; WILD TYPE; CHEMISTRY; GENE SILENCING; GENE TRANSFER; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN QUATERNARY STRUCTURE;

ALLELES; BASE SEQUENCE; CELLS, CULTURED; CORNEAL DYSTROPHY, JUVENILE EPITHELIAL OF MEESMANN; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; KERATINS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PROTEIN STRUCTURE, QUATERNARY; RNA, SMALL INTERFERING;

EID: 83155167571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028582     Document Type: Article

References (35)

1. Meesmann A, (1938) Über eine bisher nicht beschriebene dominant vererbte Dystrophia epithelialis corneae. Ber Zusammenkunft Dtsch Ophthalmol Ges 52: 154-158.
2. Irvine AD, McLean WHI, (1999) Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 140: 815-828.
3. Irvine AD, Corden LD, Swensson O, Swensson B, Moore JE, et al. (1997) Mutations in cornea-specific keratins K3 or K12 cause Meesmann's corneal dystrophy. Nat Genet 16: 184-187.
4. Szeverenyi I, Cassidy AJ, Chung CW, Lee BT, Common JE, et al. (2008) The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat 29: 351-360.
5. Omary MB, Coulombe PA, McLean WHI, (2004) Intermediate filament proteins and their associated diseases. N Engl J Med 351: 2087-2100.
6. Chiou AG, Florakis GJ, Copeland RL, Williams VA, McCormick SA, et al. (1998) Recurrent Meesmann's corneal epithelial dystrophy after penetrating keratoplasty. Cornea 17: 566-570.
7. Goldberg A, Schlotzer-Schrehardt U, Seiler T, (1997) Unilateral Meesmann's dystrophy. Int Ophthalmol 21: 117-120.
8. Irvine AD, Coleman CM, Moore JE, Swensson O, Morgan SJ, et al. (2002) A novel mutation in KRT12 associated with Meesmann's epithelial corneal dystrophy. Br J Ophthalmol 86: 729-732.
9. Bumcrot D, Manoharan M, Koteliansky V, Sah DW, (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
10. Kaspar RL, (2005) Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc 10: 62-66.
11. Lewin AS, Glazer PM, Milstone LM, (2005) Gene therapy for autosomal dominant disorders of keratin. J Investig Dermatol Symp Proc 10: 47-61.
12. Corden LD, Swensson O, Swensson B, Smith FJD, Rochels R, et al. (2000) Molecular genetics of Meesmann's corneal dystrophy: ancestral and novel mutations in keratin 12 (K12) and complete sequence of the human KRT12 gene. Exp Eye Res 70: 41-49.
13. Franke WW, Schmid E, Osborn M, Weber K, (1978) The intermediate-sized filaments in rat kangaroo PtK2 cells. II. Structure and composition of isolated filaments. Cytobiologie 17: 392-411.
14. Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, et al. (1991) Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: Genetic and functional analysis. Cell 66: 1301-1311.
15. Smith FJD, Fisher MP, Healy E, Rees JL, Bonifas JM, et al. (2000) Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. Exp Dermatol 9: 170-177.
16. Smith FJD, Porter RM, Corden LD, Lunny DP, Lane EB, et al. (2002) Cloning of human, murine, and marsupial keratin 7 and a survey of K7 expression in the mouse. Biochem Biophys Res Commun 297: 818-827.
17. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771.
18. Smith FJD, Hickerson RP, Sayers JM, Reeves RE, Contag CH, et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128: 50-58.
19. Lane EB, McLean WHI, (2008) Broken bricks and cracked mortar - epidermal diseases resulting from genetic abnormalities. Drug Discovery Today: Disease Mechanisms 5: e93-e101.
20. Leachman SA, Hickerson RP, Hull PR, Smith FJ, Milstone LM, et al. (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51: 151-157.
21. Dykxhoorn DM, Lieberman J, (2006) Knocking down disease with siRNAs. Cell 126: 231-235.
22. Kawamata T, Tomari Y, (2010) Making RISC. Trends Biochem Sci 35: 368-376.
23. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T, (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 20: 6877-6888.
24. Hao J, Li SK, Kao WW, Liu CY, (2010) Gene delivery to cornea. Brain Res Bull 81: 256-261.
25. McLean WHI, Moore CBT, (2011) Keratin disorders - from gene to therapy. Human Mol Genet 20 (R2): R189-97.
26. Yokota T, Miyagishi M, Hino T, Matsumura R, Tasinato A, et al. (2004) siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem Biophys Res Commun 314: 283-291.
27. Hickerson RP, Smith FJD, Reeves RE, Contag CH, Leake D, et al. (2008) Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128: 594-605.
28. Kao WW, Liu CY, Converse RL, Shiraishi A, Kao CW, et al. (1996) Keratin 12-deficient mice have fragile corneal epithelia. Invest Ophthalmol Vis Sci 37: 2572-2584.
29. Rugg EL, McLean WH, Lane EB, Pitera R, McMillan JR, et al. (1994) A functional "knockout" of human keratin 14. Genes Dev 8: 2563-2573.
30. Korvatska E, Henry H, Mashima Y, Yamada M, Bachmann C, et al. (2000) Amyloid and non-amyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein. J Biol Chem 275: 11465-11469.
31. Munier FL, Frueh BE, Othenin-Girard P, Uffer S, Cousin P, et al. (2002) BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci 43: 949-954.
32. Boutboul S, Black GC, Moore JE, Sinton J, Menasche M, et al. (2006) A subset of patients with epithelial basement membrane corneal dystrophy have mutations in TGFBI/BIGH3. Hum Mutat 27: 553-557.
33. Hanna C, O'Brien JE, (1960) Cell production and migration in the epithelial layer of the cornea. Arch Ophthalmol 64: 536-539.
34. Basehoar G, Berns MW, (1973) Cloning of rat kangaroo (PTK2) cells following laser microirradiation of selected mitotic chromosomes. Science 179: 1333-1334.
35. Rugg EL, (1994) Detection and characterization of keratins by immunocytochemistry and immunoblotting. In: Leigh IM, Lane EB, Watt FM, editors. Keratinocyte Methods Cambridge Cambridge University Press pp. 127-148.